Prevention of Benign Prostatic Hyperplasia Disease

Journal of Urology

Volumn 176, Issue 4, 2006, Pages 1299-1306

  Marks, Leonard S ^a   Roehrborn, Claus G ^b   Andriole, Gerald L ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 alpha reductase; dutasteride; finasteride; prostate; prostatic hyperplasia

Indexed keywords

ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE;

AGING; ARTICLE; BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; DATA BASE; DISEASE COURSE; DISEASE MARKER; EJACULATION; GENITAL SYSTEM DISEASE; GYNECOMASTIA; HUMAN; INFECTION; LIBIDO DISORDER; LIFESTYLE; MORBIDITY; PENIS ERECTION; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; PROSTATECTOMY; RISK; RISK ASSESSMENT; URINARY DYSFUNCTION; URINE FLOW RATE; URINE RETENTION;

ADULT; AGED; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; RISK ASSESSMENT;

EID: 33748098875     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.06.022     Document Type: Article

References (45)

1. Marks L.S. Treatment of men with minimally symptomatic benign prostatic hyperplasia-PRO. the argument in favor. Urology 62 (2003) 781
2. Kaplan S.A. Medical therapy for asymptomatic men with benign prostatic hyperplasia. primum non nocere. Urology 62 (2003) 784
3. Di Silverio F., Gentile V., Pastore A.L., Voria G., Mariotti G., and Sciarra A. Benign prostatic hyperplasia. what about a campaign for prevention?. Urol Int 72 (2004) 179
4. Rhodes T., Girman C.J., Jacobsen S.J., Roberts R.O., Guess H.A., and Lieber M.M. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol 161 (1999) 1174
5. Girman C.J., Panser L.A., Chute C.G., Oesterling J.E., Barrett D.M., Chen C.C., et al. Natural history of prostatism. urinary flow rates in a community-based study. J Urol 150 (1993) 887
6. Homma Y., Imajo C., Takahahi S., Kawabe K., and Aso Y. Urinary symptoms and urodynamics in a normal elderly population. Scand J Urol Nephrol Suppl 157 (1994) 27
7. Williams A.M., Simon I., Landis P.K., Moser C., Christens-Barry W., Carter H.B., et al. Prostatic growth rate determined from MRI data. age-related longitudinal changes. J Androl 20 (1999) 474
8. Wright E.J., Fang J., Metter E.J., Partin A.W., Landis P., Chan D.W., et al. Prostate specific antigen predicts the long-term risk of prostate enlargement. results from the Baltimore Longitudinal Study of Aging. J Urol 167 (2002) 2484
9. Barry M.J., Fowler F.J., Bin L., Pitts J.C., Harris C.J., and Mulley A.G. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol 157 (1997) 10
10. Jacobsen S.J., Girman C.J., and Lieber M.M. Natural history of benign prostatic hyperplasia. Urology 58 suppl (2001) 5
11. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 170 (2003) 530
12. Roehrborn C.G., Bruskewitz R., Nickel G.C., Glickman S., Cox C., Anderson R., et al. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. characterisation of patients and ultimate outcome. Eur Urol 37 (2000) 528
13. Lucas M.G., Stephenson T.P., and Nargund V. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int 95 (2005) 354
14. Baum N.H. How to work up hematuria of unknown origin?. Postgrad Med 118 (2005) 4
15. Miller M.I., and Puchner P.J. Effects of finasteride on hematuria associated with benign prostatic hyperplasia. long-term follow-up. Urology 51 (1998) 237
16. Hochberg D.A., Basillote J.B., Armenakas N.A., Vasovic L., Shevchuk M., Pareek G., et al. Decreased suburethral prostatic microvessel density in finasteride treated prostates. a possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol 167 (2002) 1731
17. Garraway W.M., Russell E.B., Lee R.J., Collins G.N., McKelvie G.B., Hehir M., et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract 43 (1993) 318
18. Roberts R.O., Rhodes T., Panser L.A., Girman C.J., Chute C.G., Oesterling J.E., et al. Natural history of prostatism. worry and embarrassment from urinary symptoms and health care-seeking behavior. Urology 43 (1994) 621
19. Roehrborn C.G., Boyle P., Gould A.L., and Waldstreicher J. Serum prostate-specific antigen as a predictor of prostatic volume in men with benign prostatic hyperplasia. Urology 53 (1999) 581
20. Roehrborn C.G., Boyle P., Bergner D., Gray T., Gittelman M., Shown T., et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate. results of a four-year, randomized trial comparing finasteride versus placebo. Urology 54 (1999) 662
21. Roehrborn C.G., McConnell J.D., Lieber M.M., Kaplan S., Geller J., Malek G.H., et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 53 (1999) 473
22. Roehrborn C.G., Malice M.P., Cook T.J., and Girman C.J. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH. a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 58 (2001) 210
23. Bosch J.L., Bohnen A.M., and Groeneveld F.P. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years. the Krimpen Study. Eur Urol 46 (2004) 753
24. McConnell J.D., Roehrborn C.G., Bautista O.M., Andriole G.L., Dixon C.M., Kusek J.W., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387
25. Jacobsen S.J., Jacobson D.J., Girman C.J., Roberts R.O., Rhodes T., Guess H.A., et al. Natural history of prostatism. risk factors for acute urinary retention. J Urol 158 (1997) 481
26. Carter H.B., Landis P., Wright E.J., Parsons J.K., and Metter E.J. Can a baseline prostate specific antigen level identify men who will have lower urinary tract symptoms later in life?. J Urol 173 (2005) 2040
27. Bartsch G., Rittmaster R.S., and Klocker H. Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 37 (2000) 367
28. Carson C., and Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61 (2003) 2
29. Bruchovsky N., Sadar M.D., Akakura K., Goldenberg S.L., Matsuoka K., and Rennie P.S. Characterization of 5alpha-reductase gene expression in stroma and epithelium of human prostate. J Steroid Biochem Mol Biol 59 (1996) 397
30. Thigpen A.E., Silver R.I., Guileyardo J.M., Casey M.L., McConnell J.D., and Russell D.W. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 92 (1993) 903
31. Thomas L.N., Douglas R.C., Vessey J.P., Gupta R., Fontaine D., Norman R.W., et al. 5α-Reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol 170 (2003) 2019
32. Grino B.B., Griffen J.E., and Wilson J.D. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 126 (1990) 1165
33. Avodart package insert (2005), GlaxoSmithKline, Research Triangle Park
34. Proscar package insert (1998), Merck and Co, Whitehouse Station, New Jersey
35. McConnell J.D., Bruskewitz R., Walsh P., Andriole G., Lieber M., Holtgrewe H.L., et al., Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338 (1998) 557
36. Roehrborn C.G., Boyle P., Nickel J.C., Hoefner K., Andriole G., ARIA3001, and ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 (2002) 434
37. Andriole G.L., Humphrey P., Ray P., Gleave M.E., Trachtenberg J., Thomas L.N., et al. Effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 172 (2004) 915
38. Iczkowski K.A., Qiu J., Qian J., Somerville M.C., Rittmaster R.S., Andriole G.L., et al. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology 65 (2005) 76
39. Marks L.S., Partin A.W., Dorey F.J., Gormley G.J., Epstein J.I., Garris J.B., et al. Long-term effects of finasteride on prostate tissue composition. Urology 53 (1999) 574
40. Kaplan S.A., Garvin D., Gilhooly P., Koppel M., Labasky R., Milsten R., et al. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. Urology 56 (2000) 610
41. Andriole G.L., and Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 44 (2003) 82
42. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215
43. Bostwick D.G., Qian J., Civantos F., Roehrborn C.G., and Montironi R. Does finasteride alter the pathology of the prostate and cancer grading?. Clin Prostate Cancer 2 (2004) 228
44. Thompson, I. M.: New insights and developments from the Prostate Cancer Prevention Trial: the promise of SELECT. Available at http://webcasts.prous.com/aua2005. Accessed July 19, 2005
45. Andriole G.L., Roehrborn C.G., Schulman C., Slawin K.M., Somerville M., and Rittmaster R.S. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 64 (2004) 537